The chemokine family has been revealed to be involved in the pathogenesis of neuropathic pain. In this study, the authors investigated the role of chemokine (C-C motif) ligand 3 and its receptors chemokine (C-C motif) receptor 1 and chemokine (C-C motif) receptor (CCR) 5 in neuropathic pain.
A spinal nerve injury model was established in adult male Wistar rats. The von Frey test and hot plate test were performed to evaluate neuropathic pain behavior, and real-time quantitative reverse transcription polymerase chain reaction, in situ hybridization, and immunohistochemistry were performed to understand the molecular mechanisms.
The expression levels of chemokine (C-C motif) ligand 3 and CCR5 messenger RNA in the spinal cord were up-regulated after nerve injury, which was possibly due to CD11b-positive microglia. Single intrathecal administration of recombinant chemokine (C-C motif) ligand 3 produced biphasic tactile allodynia; each phase of pain behavior was induced by different receptors. Intrathecal injection of CCR5 antagonist suppressed the development of tactile allodynia (12.81 ± 1.33 g vs. 3.52 ± 0.41 g [mean ± SEM, drug vs. control in paw-withdrawal threshold]; P < 0.05, n = 6 each) and could reverse established tactile allodynia (10.87 ± 0.91 g vs. 3.43 ± 0.28 g; P < 0.05, n = 8 and 7). Furthermore, Oral administration of CCR5 antagonist could reverse established tactile allodynia (8.20 ± 1.27 g vs. 3.18 ± 0.46 g; P < 0.05, n = 4 each).
Pharmacological blockade of CCR5 was effective in the treatment of the development and maintenance phases of neuropathic pain. Thus, CCR5 antagonists may be potential new drugs for the treatment of neuropathic pain.
Chemokines, small heparin-binding proteins, are up-regulated in the spinal cord after peripheral nerve injury
Their role in the development of nerve injury–induced neuropathic pain is incompletely understood
In a spinal nerve ligation injury model, neutralization of the chemokine (C-C motif) ligand 3 or administration of an antagonist of its receptor chemokine (C-C motif) receptor 5 attenuated development of early- and late-phase tactile allodynia
Antagonists of chemokine (C-C motif) receptor 5 may be a novel therapeutic approach to the treatment of neuropathic pain
NEUROPATHIC pain is a debilitating pain state, which is often caused by injury to the nervous system arising from bone compression in cancer, diabetes mellitus, infection, autoimmune disease, or physical injury.1 From general population studies, neuropathic pain affects up to 5% of the population.2,3 Hallmark symptoms of neuropathic pain include tactile allodynia and thermal hyperalgesia, which are refractory to currently available treatments such as nonsteroidal antiinflammatory drugs and opioids.4,5 The mechanism underlying the development of neuropathic pain remains largely unknown. Therefore, unraveling the molecular and cellular basis of the development and maintenance of neuropathic pain is essential for the discovery of new treatments.
Accumulating evidence from studies using animal models of neuropathic pain indicates that neuropathic pain is a reflection of aberrant excitability of dorsal horn neurons evoked by peripheral sensory input.6,7 This hyperexcitability might result from multiple cellular and molecular alternations in the dorsal horn after nerve injury. It has been suggested that there are relevant changes in neurons, but recent studies provide convincing evidence that spinal microglia, immune-like glial cells in the central nervous system (CNS), respond to peripheral nerve injury (PNI). These cells have been suggested to become morphologically activated, increase their number, and express a variety of genes required for inflammatory responses.8–12
Chemokines are small heparin-binding proteins with conserved cysteine residues in their amino acid sequences. The approximately 50 human chemokines are classified into four families (CC, CXC, CX3C, and XC family) on the basis of the presence and position of the first cysteine residue. Animal models of pain studies have revealed that several molecules of the chemokine family are involved in the pathogenesis of neuropathic and inflammatory pain.13–20 Chemokine (C-C motif) ligand (CCL) 2 was detected in the soma and processes of dorsal root ganglion neurons, and intrathecal administration of exogenous CCL2 induced rapid and sustained thermal hyperalgesia and mechanical allodynia through chemokine (C-C motif) receptor (CCR) 2.20 CCL21 was also detected in the soma and processes of injured dorsal root ganglion neurons and was transported into the dorsal horn, which participates in the up-regulation of P2X4 receptors in spinal microglia.21 Chemokine (C-X3-C motif) ligand 1, which is liberated by the microglia-derived protease cathepsin S from neuronal cell surface activated chemokine (C-X3-C motif) receptor 1 on microglia, leads to further release of microglial mediators to establish the chronic pain state.14 In the peripheral site, CCL4 correlates with neuropathic pain behavior after sciatic nerve injury in mice. CCL4 messenger RNA (mRNA) was significantly up-regulated in the injured nerve and neutralizing CCL4 in the injured nerve attenuated mechanical allodynia (not thermal hyperalgesia).17 CCL3 was also found to be up-regulated in the peripheral and CNS after PNI and contributed to chronic pain.22,23 CCL3 and CCL4 share the receptors CCR1 and CCR5. These studies propose that the chemokine receptors might be the therapeutic targets for neuropathic pain in the periphery. However, the roles of these ligands and receptors in the spinal cord remain unknown. In the current study, we sought to find the detailed role of CCL3 and its interaction with the receptors CCR1 and CCR5 in neuropathic pain and to determine their therapeutic potential in disturbing CCL3 signaling in the mechanism of tactile allodynia and thermal hyperalgesia.
Materials and Methods
Male Wistar rats (weighing 250 to 270 g; Japan SLC, Shizuoka, Japan) were housed in individual cages at a temperature of 22° ± 1°C with a 12-h light–dark cycle (light on 8:00 to 20:00) and fed food and water ad libitum. All animal experiments were conducted according to the relevant national and international guidelines and the “Act on Welfare and Management of Animals” (Ministry of Environment of Japan, Chiyoda-ku,Tokyo, Japan), “Regulation of Laboratory Animals” (Kyushu University, Higashi-ku, Fukuoka, Japan), and “Guide for the Care and Use of Laboratory Animals” (National Institutes of Health, Bethesda, Maryland). All protocols were approved by the Institutional Animal Care and Use committee review panels at Kyushu University (Fukuoka, Fukuoka, Japan).
Neuropathic Pain Model
We used the spinal nerve injury model24 with some modifications.11,25 In brief, a small left-side incision at L3–S1 was made with isoflurane (2% [v/v]) anesthesia. The paraspinal muscle and fat were removed from the L6 traverse process, and part of this traverse process was removed to expose the parallel-lying L4 and L5 spinal nerves. The left L5 spinal nerve was tightly ligated with 5-0 silk and cut just distal to the ligature. The wound and the surrounding skin were sutured with 3-0 silk.
Real-time Quantitative Reverse Transcription Polymerase Chain Reaction Analysis
Rats were deeply anesthetized with pentobarbital (100 mg/kg, intraperitoneally), perfused transcardially with phosphate buffered saline (PBS), and the L5 spinal cord was immediately removed and separated half at middle of the spinal cord, so that a sample contained the dorsal and ventral horn of the ipsilateral or contralateral side to the PNI. Total RNA from the L5 spinal cord was extracted using Trisure (Bioline, Danwon-Gu, Korea) according to the manufacturer’s protocol. For sorting CD11b-positive cells, the removed half of the L5 spinal cord was digested with Liberase DL enzyme mix (2 Wünsch units/ml in hank balanced salt solution; Roche, Basel, Switzerland) for 20 min at 37°C, triturated gently, incubated with 1 mg/ml DNase I (Roche) for 5 min at 37°C, triturated, filtered through a 70-μm cell strainer, and centrifuged (600g, 4°C) for 5 min. Myelin debris was removed by magnetic separation using Myelin Removal Beads II and MACS LS column (Miltenyi Biotec, Bergisch-Gladbach, Germany) according to the manufacturer’s protocol. After cells were washed and resuspended in PBS with 1% (v/v) fetal bovine serum, cells were incubated with anti-rat CD11b/c antibody conjugated to allophycocyanin (1:100; BioLegend, San Diego, CA) on ice. Six thousand CD11b/c-positive single cells, which is approximately 70 to 100% of total CD11b/c-positive cells isolatable from our procedure, were counted and isolated in each samples by FACSAria III (BD Biosciences, San Jose, CA). Total RNA from sorted cells were extracted and purified with the NucleoSpin RNA XS kit (Takara, Otsu, Japan). First-strand complementary DNA was reverse transcribed with Prime Script reverse transcriptase (Takara). Quantitative reverse transcription polymerase chain reaction was carried out using a 7500 real-time polymerase chain reaction analysis system (Applied Biosystems, Foster City, CA) according to the manufacturer’s protocol, and the data were analyzed using the 7500 System SDS Software 1.3.1 (Applied Biosystems). All values except for the sorted samples were normalized to glyceraldehyde-3-phosphate dehydrogenase. Expression values from sorted cells were normalized to the total cell number in the sample (6,000 cells). Results of reverse transcription polymerase chain reaction analysis were shown in figure 1, and sequences for the TaqMan probe and forward and reverse primers used in this study were designed as indicated in table 1.
Fluorescent In Situ Hybridization (ViewRNA Assay)
Rat CCL3 mRNA expression was detected using the QuantiGene® ViewRNA tissue assay (Affymetrix Panomics, Fremont, CA) according to the manufacturer’s instructions with optimal conditions of boiling in Affymetrix pretreatment solution and protease digestion. Rat CCL3 probes were purchased from Affymetrix Panomics (cat. No. VC1-11302). In brief, rat lumbar spinal cord tissues were fixed in 4% (w/v) PBS-buffered paraformaldehyde and embedded in OCT Compound (SAKURA finetek, Tokyo, Japan) and sectioned into 12-μm thick sections. The tissue slides were treated with protease at 40°C for 20 min. The RNA probe was used at a 1:40 dilution and was incubated with sample at 40°C for 120 min. After washing, the RNA/probe complex was hybridized with preamplifier, amplifier, and alkaline phosphatase–conjugated oligonucleotides at 40°C for 25, 15, and 15 min, respectively. After the removal of free alkaline phosphatase–conjugated oligonucleotide by washing in PBS, the slides were incubated with Fast Red substrate at room temperature for 30 min. The tissue images were acquired with a confocal microscope (LSM 5 Pascal; Carl Zeiss, Jena, Germany) and analyzed using the Zeiss LSM Image Browser (Carl Zeiss).
Measurement of Mechanical Paw-withdrawal Threshold (von Frey Test).
Tactile allodynia was evaluated using the von Frey test. Rats were placed individually in a wire mesh cage and habituated for 30 to 60 min to allow acclimatization to the new environment.11,25 Calibrated von Frey filaments (0.4 to 15 g; Stoelting, Wood Dale, IL) were applied to the plantar surface of the rat hind paw from below the mesh floor. The 50% paw-withdrawal threshold (PWT) was determined using the up–down method.26
Measurement of Thermal Hyperalgesia (Hot Plate Test).
Thermal hyperalgesia was evaluated using the hot plate test. Rats were placed individually on a hot plate metallic surface maintained at 52°C, and the time between placement of the animal on the hot plate and the occurrence of either licking or shaking of each hind paw was recorded as the reaction time (s). The cutoff time was assessed at 60 s. The measurements were repeated three times at 30-min intervals, and the average of the measurements was used in the final analysis.
Intrathecal Drug Administration.
For intrathecal drug administration, with isoflurane (2% [v/v]) anesthesia, a 32-gauge intrathecal catheter (ReCathCo, Allison Park, PA) was inserted through the atlanto-occipital membrane into the lumbar enlargement and externalized through the skin.25 Four days after catheterization, the catheter placement was verified by the observation of hind limb paralysis after intrathecal injection of lidocaine (2% [v/v], 5 μl). Animals that failed to display paralysis by lidocaine were not included in the experiments. The below-mentioned experiments were performed at least 2 to 3 days after the lidocaine test.
Behavioral Test Procedure.
First, rats were injected with recombinant CCL3 (rCCL3, 0.1 and 10 fmol/10 μl in PBS; Peprotech, Rocky Hill, NJ) once through the catheter, and behavioral measurements were carried out 30 min before, 30, 60, 120, 180, 240, 300 min, and 1, 3, 5, 7, 14 days after drug administration (fig. 2). For examining the effect of CCR1 or CCR5 antagonists on rCCL3-induced tactile allodynia, preinjection (30 min before intrathecal injection of rCCL3) of the selective CCR1 antagonist BX513 hydrochloride (0.01, 0.1, and 1 pmol/10 μl; Tocris Bioscience, Bristol, United Kingdom) or the selective CCR5 antagonist maraviroc (Selzentry, Celsentri) (1, 10, and 100 pmol/10 μl; Sellek, Houston, TX) was performed. In another experiment, BX513 hydrochloride was injected 1 day after CCL3 injection, and behavioral measurements were carried out as described above (fig. 3).
For examining the effect of CCL3-neutralizing antibody, CCR1, or CCR5 antagonists on development of neuropathic pain, the unilateral L5 spinal nerve of rats was injured as described above, and rats were intrathecally injected with CCL3-neutralizing antibody (20 ng in 10 μl; Roche) once a day from 1 day before PNI to 3 days after PNI or either maraviroc or BX513 hydrochloride once a day from day 0 (just before nerve injury) up to day 6. The behavioral measurements were carried out before PNI and on days 1, 3, 5, and 7 (individual measurements carried out before daily injection of the drugs to prevent observing acute effects of the drug injection) (fig. 4). Furthermore, for examining the effect of CCL3-neutralizing antibody, BX513 hydrochloride or maraviroc on the established tactile allodynia, CCL3-neutralizing antibody, BX513 hydrochloride, or maraviroc were injected from day 7 to day 13 after PNI. Behavioral measurements were carried out 7 days after PNI, 30, 60, 120, 180, 240, 300 min, and 1, 3, 5, 7 days after first drug administration (fig. 5, A–C). Single maraviroc injections were also performed after 7 days after PNI, and behavioral measurements were carried out for 3 days after the injection (8, 9, and 10 days after PNI; fig. 5D). The hot plate test was carried out before PNI, 3 and 7 days after PNI, or 3 and 24 h after drug administration in animals that received PNI 7 days before the injection (fig. 6).
For examination of oral administration of maraviroc on existing tactile allodynia, maraviroc (100 mg/kg, suspended in 0.5% [w/v] carboxymethyl cellulose) was orally administered (by gavage) 7 days after PNI, and behavioral measurements were carried out 30, 60, 120, 180, 240, 300, 360 min, and 1, 2, 3, 5 days after drug administration (fig. 7).
Rats were deeply anesthetized with pentobarbital (100 mg/kg, intraperitoneally) and perfused transcardially with 100 ml of PBS, followed by 150 ml of ice-cold 4% (w/v) paraformaldehyde/PBS. The L5 segment of the spinal cord was removed, postfixed in the same fixative for 3 h at 4°C, and placed in 30% (w/v) sucrose solution for 24 h at 4°C. The transverse spinal cord sections (30 μm) were cut. The sections were incubated for 48 h at 4°C with the primary antibody OX-42 (rat monoclonal 5C6, 1:1,000; Serotec, Oxford, United Kingdom). After incubation, the sections were washed and incubated with the appropriate secondary antibody (Alexa Fluor 543 conjugated with goat anti-rat/rabbit IgG, 1:1,000; Life Technologies Japan Ltd., Tokyo, Japan). Fluorescent images were obtained with a confocal microscope (LSM 5 Pascal; Carl Zeiss) and analyzed using the Zeiss LSM Image Browser (Carl Zeiss).
Data are presented as the mean ± SEM. Statistical analyses were computed using the software SigmaPlot (build 184.108.40.206; Systat Software, Inc., Chicago, IL) using one-way ANOVA post hoc Tukey multiple comparisons, two-way ANOVA followed by Bonferroni multiple comparisons test, or paired t tests. The values were considered significantly different at P value less than 0.05.
Up-regulation of CCL3 and CCR5 mRNA Expression in the Spinal Cord after PNI
Using real-time quantitative reverse transcription polymerase chain reaction, we examined the levels of CCL3, CCR1, and CCR5 mRNA in total RNA extracts from the spinal cord ipsilateral and contralateral to injury at the L5 spinal nerve (fig. 1). A significant increase in CCL3 mRNA expression in the ipsilateral spinal cord was observed 1, 10, and 14 days after PNI (P < 0.01, P < 0.05, P < 0.001) (fig. 1A). The expression of CCR5 mRNA in the ipsilateral spinal cord significantly increased from 1 to 14 days after PNI (fig. 1B), and an increase in protein expression at day 7 after PNI was suggested by Western blotting (see fig. 1, Supplemental Digital Content 1, http://links.lww.com/ALN/B36, and Supplemental Digital Content 2, http://links.lww.com/ALN/B37). In contrast, CCR1 mRNA expression in the spinal cord remained unchanged statistically (fig. 1C). It is widely accepted that spinal microglia are activated after PNI and that microglia have the potential to be a source of inflammatory mediators including chemokines. Thus, we collected CD11b/c-positive cells from the rat spinal cord 20 h after PNI using flow cytometric cell sorting. Detected CCL3 mRNA expression levels were significantly higher on the ipsilateral side to PNI (fig. 1D). Localization of CCL3 mRNA detected by fluorescent in situ hybridization indicated that mRNA expression indicated by red spots was apparently increased in the dorsal horn (fig. 1, E–N). Signals in the dorsal horn of the spinal cord ipsilateral side to the PNI existed more densely around innervating nerve bundles recognized by scattering structures in the transmitted light image (fig. 1M). However, we failed to detect protein expression of CCL3 by immunohistochemistry or Western blotting (data not shown). These results represent that at least in part spinal microglia in the dorsal horn may enhance the expression of CCL3 mRNA after PNI.
We could not identify the responsible cell types for CCR1 and CCR5 mRNA expression, but it was expected that different cell types in the spinal cord express CCR1 or CCR5, because chromogenic in situ hybridization assays revealed distinct staining patterns for each receptor mRNA (see figs. 2 and 3, Supplemental Digital Content 1, http://links.lww.com/ALN/B36, and Supplemental Digital Content 2, http://links.lww.com/ALN/B37). Flow cytometric analysis showed that spinal CD11b/c-positive cells had surface expression of CCR5 receptor protein, but expression levels did not change between the ipsilateral and contralateral side at day 3 (unpublished result, October 14, 2013, Katsuyuki Matsushita, M.D., Fukuoka, Fukuoka, Japan). The increased number of CCR5 mRNA-positive cells was obvious on the ipsilateral side of the dorsal horn. Thus, it was suggested that CCR5 was expressed basally in the spinal microglia, but the expression levels were not altered at a single-cell level. The detected increase in CCR5 mRNA expression in total RNA from whole spinal tissue samples may be due to the increases in the number of spinal microglia on the ipsilateral side to the PNI.
We also examined the expression of interleukin 6 and tumor necrosis factor-α mRNA at 16 and 20 h after PNI. The transcripts of these genes were significantly increased at both time points. Thus, it is suggested that some inflammatory responses were induced as early as 16 h after PNI (unpublished result, September 25, 2012, Katsuyuki Matsushita, M.D., Fukuoka, Fukuoka, Japan).
Development of Tactile Allodynia by Intrathecal Injection of rCCL3
To investigate the effect of CCL3 up-regulation on the spinal cord during neuropathic pain, we performed a single intrathecal injection of rCCL3 to naive rats. Single intrathecal injection of rCCL3 produced two phases of tactile allodynia behavior (fig. 2). In the first phase, the PWT to mechanical stimulation decreased during the first 60 min (3.18 ± 0.46 g in 10-fmol treated rats and 14.49 ± 0.50 g in vehicle-treated rats; P < 0.001) and gradually recovered. At 5 h after injection, significant recovery of PWT from a peak decrease was observed. In the second phase, the decreased PWT was again observed at 24 h after rCCL3 injection (P < 0.001; 5.28 ± 0.58 g in 10-fmol treated rats and 13.72 ± 0.83 g in vehicle-treated rats) and persisted to day 7 (P < 0.01; 6.52 ± 1.16 g in 10-fmol treated rats and 13.24 ± 0.82 g in vehicle-treated rats) after injection. PWT recovered 14 days after intrathecal injection. It should be noted that a lower dose of rCCL3 produced only a later phase of PWT decrease. Thus, each phase of pain behavior may not be a sequential incident, but different mechanisms induced each behavior.
CCR1 and CCR5 Antagonists Inhibited rCCL3-induced Tactile Allodynia
CCL3 is known to be the ligand for CCR1 and CCR5, and mRNAs of these receptors were differentially expressed in the spinal cord. Thus, to investigate the detailed role of CCR1 and CCR5 in rCCL3-induced tactile allodynia, the CCR1 antagonist BX513 hydrochloride or the CCR5 antagonist maraviroc were intrathecally injected 30 min before intrathecal injection of rCCL3. In maraviroc pretreated rats, the first phase of rCCL3-induced tactile allodynia was not suppressed. However, in the second phase of rCCL3-induced tactile allodynia, maraviroc dose-dependently suppressed the decrease of PWT from day 1 (P < 0.05; 9.45 ± 1.04 g in 100-pmol treated rats and 5.61 ± 0.65 g in vehicle-treated rats) up to day 7 after injection (P < 0.001; 11.49 ± 0.88 g in 100-pmol treated rats and 5.99 ± 0.93 g in vehicle-treated rats) (fig. 3A). In contrast, in BX513 hydrochloride pretreated rats, the first phase of rCCL3-induced tactile allodynia was clearly suppressed in a dose-dependent manner. However, the second phase was not affected at all (fig. 3B). It should be noted that this transient effect of BX513 hydrochloride was also observed at the second phase of rCCL3-induced tactile allodynia. When BX513 hydrochloride was intrathecally injected 1 day after intrathecal injection of rCCL3, the rCCL3-induced decreased PWT transiently recovered (fig. 3C) (P < 0.001; 9.45 ± 0.88 g in 1-pmol BX513 hydrochloride–treated rats and 3.77 ± 0.24 g in vehicle-treated rats). The PWT decreased again 120 min after BX513 hydrochloride injection. These results suggest that CCL3 has dual effects on pain induction: acute and transient effects through CCR1 and slowly develops long-lasting effects through CCR1 and CCR5.
The CCR5 Antagonist and CCL3-neutralizing Antibody Attenuated the Development of PNI-induced Tactile Allodynia
To investigate whether endogenous CCL3 protein is involved in the mechanism of developing neuropathic pain, we intrathecally injected CCL3-neutralizing antibody to rats with developing neuropathic pain. A significant suppression of the PWT decrease was observed during the period of antibody injection, and this effect lasted at least 4 days after discontinuing the injection (the PWT on the ipsilateral side 7 days after PNI, P < 0.001; 9.34 ± 1.67 g in CCL3-neutralizing antibody-treated rats and 2.60 ± 0.53 g in vehicle-treated rats) (fig. 4A).
To investigate whether endogenous CCR1 or CCR5 is involved in the mechanism of developing neuropathic pain, we intrathecally injected BX513 hydrochloride or maraviroc in rats with developing neuropathic pain. In animals subjected to BX513 hydrochloride or maraviroc injection, reagents were intrathecally injected once a day from just before PNI to 6 days after PNI. Behavioral measurements were scheduled before daily injection to exclude the acute effects of reagents from the measurements. In maraviroc-treated rats, a significant suppression of PWT decrease was observed from 3 days to 7 days in a dose-dependent manner (fig. 4B). On day 7 after PNI, a significant decrease in PWT was observed on the ipsilateral side in vehicle-treated rats (P < 0.001; 3.52 ± 0.41 g on ipsilateral side and 12.54 ± 0.90 g on contralateral side, not shown in fig. 4, A–C). In contrast, the decreased PWT recovered in maraviroc-treated rats (12.81 ± 1.33 g on the ipsilateral side of 100-pmol maraviroc-treated rats, whereas 12.43 ± 1.32 g on the contralateral side) after PNI. In BX513 hydrochloride–treated rats, development of PNI-induced tactile allodynia was not suppressed at all (fig. 4C). To examine whether CCL3-neutralizing antibody or maraviroc affects activation of spinal microglia, we performed immunolabeling of spinal sections from antibody-treated (day 3) and maraviroc-treated (day 7) nerve-injured rats with the microglial marker OX-42. As reported previously,11 a marked increase in OX-42 immunoreactivity was observed in the ipsilateral dorsal spinal cord of vehicle-treated rats 3 and 7 days after PNI (fig. 4, D–G). In contrast to the effect of tactile allodynia, repeated intrathecal administration of either the CCL3-neutralizing antibody or maraviroc did not suppress this increase in OX-42 labeling (fig. 4, H–K).
The CCL3-neutralizing Antibody, CCR1 Antagonist, and CCR5 Antagonist Relieved Existing Tactile Allodynia
To examine whether the CCR1 antagonist or CCR5 antagonist is effective in treating tactile allodynia, we intrathecally injected BX513 hydrochloride or maraviroc once a day from day 7 to day 13 after PNI. Under these conditions, short-term behavioral tests were performed immediately after the first injection to clarify the acute effect of drugs. In BX513 hydrochloride–treated rats, the decreased PWT on the ipsilateral side increased at 60 min (P < 0.001; 9.89 ± 0.53 g in 1-pmol treated rats and 4.02 ± 0.29 g in vehicle-treated rats) after injection (fig. 5A). This effect was not observed 120 min after BX513 hydrochloride injection, and the decreased PWT was unchanged by daily administration of BX513 hydrochloride. In maraviroc-treated rats, the decreased PWT on the ipsilateral side increased 30 min after injection (P < 0.001; 10.87 ± 0.91 g in 100-pmol treated rats and 3.43 ± 0.28 g in vehicle-treated rats). Contrary to BX513 hydrochloride–treated rats, the increase in PWT persisted for 24 h after maraviroc injection dose-dependently (P < 0.001; 11.00 ± 0.42 g in 100-pmol treated rats and 3.79 ± 0.31 g in vehicle-treated rats) (fig. 5B). Daily injection of maraviroc reversed the decreased PWT on the ipsilateral side continuously in a dose-dependent manner. Single injection of maraviroc recovered the decrease in PWT on the ipsilateral side up to 1 day after injection (fig. 5D). CCL3-neutralizing antibody at the same dose that suppressed the development of tactile allodynia also reversed PWT transiently and partially. However, repeated administration showed enhanced and longer recovery effects (fig. 5C).
The CCR5 Antagonist Relieved Thermal Hyperalgesia after PNI
To investigate whether maraviroc was effective in thermal hyperalgesia, we intrathecally injected maraviroc once a day from just before PNI to 6 days after PNI. Similar to the effect on tactile allodynia, repetitive administration of maraviroc suppressed the development of thermal hyperalgesia (fig. 6A). Single administration of maraviroc to PNI rats also resulted in a significant recovery of thermal hyperalgesia (fig. 6B).
Oral Administration of the CCR5 Antagonist Relieved Established Tactile Allodynia
To examine the effect of oral administration of maraviroc on PNI-induced tactile allodynia, we performed single oral administration of maraviroc (by gavage) 7 days after PNI. The decreased PWT of rats orally administered maraviroc increased from 120 min (P < 0.001; 7.93 ± 1.16 g in maraviroc-treated rats and 3.39 ± 0.13 g in vehicle-treated rats) up to day 2 (P < 0.001; 6.07 ± 0.39 g in maraviroc-treated rats and 3.63 ± 0.12 g in vehicle-treated rats) after administration (fig. 7).
In the current study, we provide evidence that the CCL3 transcript is up-regulated in the ipsilateral dorsal spinal cord after PNI, and that CCL3 participates in the development and maintenance of neuropathic pain. Consistent with a previous study,22 neutralizing endogenous CCL3 in the spinal cord with a specific antibody prevented development of tactile allodynia after PNI. In addition, we found that established tactile allodynia recovered after repetitive intrathecal injection of CCL3-neutralizing antibody. In a pain model of partial sciatic nerve ligation, it was demonstrated that CCL2, CCL3, CCL4, and chemokine (C-X-C motif) ligand 2 were up-regulated in the injured site of sciatic nerves. Using neutralizing antibodies, it was shown that CCL3 and chemokine (C-X-C motif) ligand 2 contribute to the development of tactile allodynia and thermal hyperalgesia, but CCL4 contributes to only tactile allodynia.17,19,23,27 Several studies indicate that infiltrating immune cells produce chemokines around sciatic nerves.19,22,23 In this study, we found that CCL3 mRNA was also up-regulated in the injured side of the spinal cord, and similar up-regulation was observed in sorted CD11b/c-positive cells from the spinal cord that are considered spinal microglia. Thus, in the spinal cord, resident microglia may be one of the CCL3-producing cells that are involved in establishing tactile allodynia and thermal hyperalgesia. Because of technical limitations, we could not obtain reliable evidence for the presence and up-regulation of CCL3 protein. However, the inhibitory effect of the neutralizing antibody on pain hypersensitivity suggests the presence of endogenous CCL3 protein in the spinal cord after PNI. In parallel, we found that intrathecal administration of rCCL3 protein could produce tactile allodynia. Similar observations were demonstrated in a previous study,22 but we carried out behavioral assays to see the acute effect of rCCL3 injection and found that the rCCL3-induced tactile allodynia was a biphasic phenomenon. Single injection induces an early phase and late phase of tactile allodynia. Differences between phases have been more clearly understood from results showing that low doses of rCCL3 (0.1 fmol) do not induce early phase but a significant decrease in PWT in later phase. Indeed, we found that pretreatment with a CCR1 antagonist suppressed tactile allodynia at early phase and that CCR5 antagonist reduced allodynia in later phase. Difference in sensitivity to CCL3, which were observed in the case of low-dose rCCL3 administration, may be due to differences in cell types expressing CCR1 or CCR5. Localization of CCR1 mRNA was observed in neuron-like cells (large round cell body) at inner parts of the spinal cord (see fig. 2, Supplemental Digital Content 1, http://links.lww.com/ALN/B36), whereas CCR5 mRNA was observed in small cells that increased in number on the injured side of the spinal cord and surrounded large motor neuron-like cells in the ventral horn (see fig. 3, Supplemental Digital Content 1, http://links.lww.com/ALN/B36). In addition, we observed that mRNA of CCR5 was up-regulated on the ipsilateral spinal cord after PNI, but CCR1 was unchanged (fig. 1). Thus, it was considered that each receptor was differentially expressed and regulated in the spinal cord because of the different cell types expressing each receptor or because of the difference in mechanism regulating receptor transcription. Together with these observations, it is suggested that CCR1 stimulates CCR1-mediated transient pain signaling and CCR5 triggers the development of relatively long-lasting tactile allodynia. It should be noted that the CCR1 antagonist showed transient relief to later phase of allodynia, but this effect was reversed within a few hours (fig. 3C). It seems unlikely that intrathecally injected rCCL3 maintains an effective concentration in the spinal cord a day after injection. Thus, it may be implicated that CCR5-triggered later-phase tactile allodynia is mediated by CCR1-induced pain signaling or that basal CCR1 activity is required for pain sensation.
Blockade of CCR5 successfully suppressed the development of tactile allodynia. Several previous studies also demonstrated the availability of CCR5 inhibition for treating tactile allodynia after PNI or inflammation.17,18,28,29 We found that both the CCR1 antagonist and CCR5 antagonist immediately removed established tactile allodynia. However, the effect of the CCR1 antagonist was transient, and daily administration of the CCR1 antagonist was not effective to obtain successive relief from tactile allodynia after PNI. In contrast, the effect of the CCR5 antagonist was long lasting. A previous study suggested that CCR5 was expressed in spinal microglia, with CCR5 mRNA being expressed in Iba-1-positive activated microglia after partial sciatic nerve ligation.29 Our results seem to support this suggestion. Similarly, in this study, the expression of CCR5 mRNA increased in a similar manner to the increase in microglial number after PNI,30 with surface expression of CCR5 protein being detected by flow cytometry in CD11b/c-positive cells (unpublished result, October 14, 2013, Katsuyuki Matsushita, M.D., Fukuoka, Fukuoka, Japan). Although mRNA expression levels in the spinal cord were significantly increased at day 3 after PNI, we did not detect enhanced surface expression of CCR5 in CD11b/c-positive cells. However, the number of CD11b/c-positive cells increased (unpublished result, October 14, 2013, Katsuyuki Matsushita, M.D., Fukuoka, Fukuoka, Japan). These two observations suggest that up-regulation of CCR5 mRNA expression levels is due to the increase in the number of spinal microglia in response to PNI. Together, it is suggested that CCR5 in spinal cord microglia is a crucial factor for maintenance of tactile allodynia after PNI. It was reported that inhibition of microglial activation with minocycline attenuates the development but not existing hypersensitivity in a rat model of neuropathy.31 However, in our case, the CCR5 antagonist recovered established tactile allodynia and thermal hyperalgesia. We have observed similar results using an antagonist of the P2Y12 receptor which is specifically expressed in microglia32,33 and suppresses gene expression of interferon regulatory factor 8, which regulates the activation state of microglia.34 Furthermore, morphological signs of microglial activation were suppressed by minocycline, but the P2Y12 receptor antagonist did not affect the morphology of cells and increased cell number, as was observed in our current study using the CCL3-neutralizing antibody and the CCR5 antagonist (fig. 4, D–K). Therefore, it is suggested that at least some part of the cellular signaling in microglia that includes CCR5 but not the target of minocycline contributes to the maintenance of tactile allodynia after PNI. The mechanism by which CCR5 develops and maintains tactile allodynia and thermal hyperalgesia is still unknown and may include beneficial therapeutic targets for the treatment of neuropathic pain. It is also important to study the molecular mechanisms regulating CCR5 function in the spinal cord after PNI, as it was indicated in a previous study that posttranslational modification of the N-terminal of CCR5 modulates binding affinity of chemokines to CCR5.35
One intriguing point of our experiments is that maraviroc, an antagonist for CCR5, is an approved drug for the treatment of human immunodeficiency virus (HIV) infection. Maraviroc is a selective, reversible, small-molecule CCR5 antagonist for the treatment of HIV-1 infection. Maraviroc is the first member of a new class of antiretroviral medications and has been approved by the U.S. Food and Drug Administration for the use in combination with other antiretroviral agents for treatment-experienced patients infected with multidrug-resistant CCR5-toropic HIV-1. The most frequently reported (>10%) adverse effects of maraviroc are upper respiratory tract infection (20.0%), cough (12.7%), and pyrexia (12.0%).36 Tricyclic antidepressants, α2-δ anticonvulsants, serotonin, and norepinephrine reuptake inhibitors are used as a treatment of neuropathic pain,37 but these drugs are associated with several CNS-related side effects including sedation and dizziness.37,38 Dizziness has been reported as one of the side effects of maraviroc, but in comparison with currently available treatments, oral administration of maraviroc is associated with fewer CNS-related side effects. However, in our study, we have been unable to address this problem given that the dose of oral maraviroc administration was higher than that being currently used for the treatment of HIV infection, because only 10% of maraviroc in the plasma is distributed to the CNS in rats.39,40 Thus, although it is necessary to take proper account of the dose and route of administration for clinical use or new drug design, we consider that the CCL3–CCR5 signaling pathway may be a new therapeutic target for the treatment of neuropathic pain.
This work was partly supported by grants-in-aid for Scientific Research (KAKEN S-23229008 and KAKEN C-25460721) from Japan Society of the Promotion of Science (Chiyoda-ku, Tokyo, Japan; to Drs. Inoue and Tozaki-Saitoh), the Core Research for Evolutional Science and Technology (CREST) program of the Japan Science and Technology (JST) Corporation (Kawaguchi, Saitama, Japan), and Platform for Drug Discovery, Informatics, and Structural Life Science from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (Chiyoda-ku, Tokyo, Japan).
The authors declare no competing interests.